Arcus Biosciences Inc
NYSE:RCUS
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
13.69
20.18
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one RCUS stock under the Base Case scenario is 14.64 USD. Compared to the current market price of 14.7 USD, Arcus Biosciences Inc is Fairly Valued.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Arcus Biosciences Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for RCUS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Arcus Biosciences Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Arcus Biosciences Inc
Balance Sheet Decomposition
Arcus Biosciences Inc
Current Assets | 1.1B |
Cash & Short-Term Investments | 1.1B |
Receivables | 21m |
Other Current Assets | 17m |
Non-Current Assets | 125m |
Long-Term Investments | 2m |
PP&E | 48m |
Other Non-Current Assets | 75m |
Current Liabilities | 215m |
Accounts Payable | 13m |
Accrued Liabilities | 97m |
Other Current Liabilities | 105m |
Non-Current Liabilities | 472m |
Long-Term Debt | 47m |
Other Non-Current Liabilities | 425m |
Earnings Waterfall
Arcus Biosciences Inc
Revenue
|
263m
USD
|
Operating Expenses
|
-561m
USD
|
Operating Income
|
-298m
USD
|
Other Expenses
|
28m
USD
|
Net Income
|
-270m
USD
|
Free Cash Flow Analysis
Arcus Biosciences Inc
USD | |
Free Cash Flow | USD |
RCUS Profitability Score
Profitability Due Diligence
Arcus Biosciences Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Arcus Biosciences Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
RCUS Solvency Score
Solvency Due Diligence
Arcus Biosciences Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
Arcus Biosciences Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RCUS Price Targets Summary
Arcus Biosciences Inc
According to Wall Street analysts, the average 1-year price target for RCUS is 34.68 USD with a low forecast of 20.2 USD and a high forecast of 48.3 USD.
Dividends
Current shareholder yield for RCUS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
RCUS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 366 full-time employees. The company went IPO on 2018-03-15. The firm's six investigational products are in the clinical development, with its molecule, an anti-TIGIT antibody, which is in two phase III registrational studies. The firm's differentiated combination therapies are developing to treat multiple large tumor types, including lung, colorectal, prostate and pancreatic cancers. Its clinical development pipeline includes Domvanalimab, AB308, Etrumadenant, Quemliclustat, Zimberelimab and AB521. Domvanalimab is its Fc-silent anti-TIGIT monoclonal antibody. AB308 is its Fc-enabled anti-TIGIT monoclonal antibody. Etrumadenant is designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells (dendritic cells, macrophages), mediated by the A2a and A2b receptors. Quemliclustat is an extremely potent and selective small-molecule CD73 inhibitor. Zimberelimab is its anti-PD-1 antibody.
Contact
IPO
Employees
Officers
The intrinsic value of one RCUS stock under the Base Case scenario is 14.64 USD.
Compared to the current market price of 14.7 USD, Arcus Biosciences Inc is Fairly Valued.